Insights into HPV16-Positive HNSCC Treatment Innovations
In an important event for stakeholders in cancer treatment, PDS Biotechnology Corporation (NASDAQ: PDSB) will be hosting a virtual key opinion leader (KOL) event. This gathering aims to facilitate a meaningful discussion about the evolving treatment landscape for recurrent and metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).
Understanding the Landscape of HNSCC
The discussion will feature notable experts like Kevin Harrington, MBBS, PhD from The Institute of Cancer Research in the UK, and Katharine A. Price, MD from the Mayo Clinic Comprehensive Cancer Center. Their insights will clarify the unmet medical needs and current therapeutic approaches available for patients battling HPV16-positive HNSCC.
Head and neck cancers associated with HPV16 are surging in incidence across various regions, compelling the medical community to reassess treatment protocols. This event will explore insights related to the pivotal Merck’s KEYNOTE-689 (KN-689) study, placing a spotlight on the urgent necessity for effective treatment alternatives as the burden of HPV16-positive HNSCC escalates.
Versamune® HPV: A Novel Immunotherapy Approach
At the center of this discussion is PDS Biotech’s lead investigational product, Versamune® HPV. This groundbreaking immunotherapy is currently undergoing evaluation in a Phase 3 clinical trial in combination with pembrolizumab for first-line treatment in recurrent and metastatic HPV16-positive HNSCC patients. Additionally, various Phase 2 trials are assessing its efficacy across a spectrum of HPV16-associated cancers.
Versamune® HPV is designed to evoke a robust immune response targeting cancers linked with HPV, signifying a novel approach in immunotherapy aimed specifically at HPV-positive malignancies. The panelists will also delve into the pressing need to differentiate treatments between HPV-positive and HPV-negative HNSCC, underlining how the underlying biology of these cancers varies significantly.
Event Details and Participation
The webinar is scheduled, promising an informative session for healthcare professionals and interested parties. Participants will gain valuable insights into the latest advancements in treating HPV16-positive HNSCC and will have the opportunity to engage in a live Q&A session with the expert panel.
Date: Upcoming Tuesday
Time: 12:00 PM ET
Meet the Experts
Dr. Kevin Harrington leads the Division of Radiotherapy and Imaging at The Institute of Cancer Research. He has a notable background in treating advanced head and neck cancers. His involvement in the KEYNOTE-048 trial, which backed the FDA approval for pembrolizumab, marks his significant contributions to the field.
Dr. Katharine A. Price specializes in head and neck oncology and is currently researching deintensified treatments for HPV-associated throat cancers. Her commitment to improving cancer care and survivorship is reflected in her ongoing studies, making her a key voice in this essential discourse.
About PDS Biotechnology
PDS Biotechnology Corporation stands at the forefront of the immunotherapy revolution, dedicated to transforming how the immune system combats cancer. With ongoing clinical trials addressing advanced HPV16-positive HNSCC, the company is not only pushing for new treatment paradigms but is also evaluating combination therapies that leverage the potential of immune checkpoint inhibitors paired with their innovative products.
This pivotal event marks a significant step toward advancing the understanding and treatment of HPV16-positive head and neck cancers, reinforcing PDS Biotech’s commitment to addressing critical unmet needs in oncology. For further information, please visit www.pdsbiotech.com.
Frequently Asked Questions
What is the focus of the upcoming KOL event hosted by PDS Biotech?
The event will highlight key insights into the treatment landscape for HPV16-positive head and neck squamous cell carcinoma, featuring expert discussions on clinical advancements.
Who are the featured speakers at the KOL event?
The panel includes leading experts Dr. Kevin Harrington and Dr. Katharine A. Price, both of whom have substantial experience in cancer research and treatment.
When will the KOL event take place?
The event will take place on Tuesday at 12:00 PM ET, consisting of both presentations and a live Q&A session.
What is Versamune® HPV?
Versamune® HPV is an investigational immunotherapy designed to target HPV-associated cancers, currently being evaluated in clinical trials for its effectiveness in treating HNSCC.
How can I participate in the event?
Participants can register for the event by visiting PDS Biotech's website, where further details and registration instructions will be available.
